An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers

Trial Profile

An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Cetuximab
  • Indications Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms VE-BASKET
  • Sponsors Roche
  • Most Recent Events

    • 07 Aug 2017 According to a Genentech media release, the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. The FDA is expected to make a decision on approval by December 7, 2017. The sNDA application included data from this study.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (database lock 12 Jan 2017) assessing efficacy of vemurafenib presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top